ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling

The type III receptor tyrosine kinase FLT3 is one of the most commonly mutated oncogenes in acute myeloid leukemia (AML). Inhibition of mutated FLT3 in combination with chemotherapy has displayed promising results in clinical trials. However, one of the major obstacles in targeting FLT3 is the devel...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Kazi, Julhash U., Rupar, Kaja, Marhäll, Alissa, Moharram, Sausan A., Khanum, Fatima, Shah, Kinjal, Gazi, Mohiuddin, Nagaraj, Sachin Raj M., Sun, Jianmin, Chougule, Rohit A., Rönnstrand, Lars
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355336/
https://ncbi.nlm.nih.gov/pubmed/28086240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14577
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires